|
1.
|
Liu C, Zhang H, Shuang C, Lu Y, Jin F, Xu
H and Lu P: Alterations of ER, PR, HER-2/neu, and P53 protein
expression in ductal breast carcinomas and clinical implication.
Med Oncol. 27:747–752. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2.
|
Hicks DG and Kulkarni S: HER2+ breast
cancer: review of biologic relevance and optimal use of diagnostic
tools. Am J Clin Pathol. 129:263–273. 2008.
|
|
3.
|
Recăreanu F, Simionescu C, Georgescu CV
and Pirici E: Ductal invasive mammary carcinoma -
clinicopathological prognostic factors related to
immunohistochemical expression of hormonal receptors and Her2/neu
oncoprotein. Rom J Morphol Embryol. 52:1059–1064. 2011.
|
|
4.
|
Woolcott CG, SenGupta SK, Hanna WM and
Aronson KJ: Estrogen and progesterone receptor levels in
nonneoplastic breast epithelium of breast cancer cases versus
benign breast biopsy-controls. BMC Cancer. 8:1302008. View Article : Google Scholar
|
|
5.
|
Walker RA: Immunohistochemical markers as
predictive tools for breast cancer. J Clin Pathol. 61:689–696.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
6.
|
Wang ZB, Zhao P, Liu M and Li XH:
Expression of ER, PR and Cyclin D1 in breast infiltrating ductal
carcinoma and their clinicopathological significance. Zhonghua Yi
Xue Za Zhi. 85:514–517. 2005.(In Chinese).
|
|
7.
|
Wu X, Zhang X, Zhang H, et al:
Progesterone receptor down-regulates breast cancer resistance
protein expression via binding to the progesterone response element
in breast cancer. Cancer Sci. 103:959–967. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8.
|
Daniel AR, Hagan CR and Lange CA:
Progesterone receptor action: defining a role in breast cancer.
Expert Rev Endocrinol Metab. 6:359–369. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9.
|
Wargon V, Fernandez SV, Goin M, et al:
Hypermethylation of the progesterone receptor A in constitutive
antiprogestin-resistant mouse mammary carcinomas. Breast Cancer Res
Treat. 126:319–332. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10.
|
Gown AM: Current issues in ER and HER-2
testing by IHC in breast cancer. Mod Pathol. 21(Suppl 2): S8–S15.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
11.
|
Guo H and Bai O: Relationship between the
expression of ER, PR, Her -2 in breast cancer and its clinical
pathological features. Chin J Lab Diagn. 12:1390–1392. 2008.
|
|
12.
|
Bagaria SP, Ray PS, Wang J, et al:
Prognostic value of basal phenotype in HER2-overexpressing breast
cancer. Ann Surg Oncol. 19:935–940. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13.
|
Schillaci R, Guzmán P, Cayrol F, et al:
Clinical relevance of ErbB-2/HER2 nuclear expression in breast
cancer. BMC Cancer. 12:742012. View Article : Google Scholar : PubMed/NCBI
|
|
14.
|
Hussein MR, Abd-Elwahed SR and Abdulwahed
AR: Alterations of estrogen receptors, progesterone receptors and
c-erbB2 oncegene protein expression in ductal carcinomas of the
breast. Cell Biol Int. 32:698–707. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15.
|
Taucher S, Rudas M, Mader RM, et al: Do we
need HER-2/neu testing for all patients with primary breast
carcinoma? Cancer. 98:2547–2553. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
16.
|
Prat A and Baselga J: The role of hormonal
therapy in the management of hormonal-receptor-positive breast
cancer with co-expression of HER2. Nat Clin Pract Oncol. 5:531–542.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
17.
|
Murthy SS, Sandhya DG, Ahmed F, et al:
Assessment of HER2/Neu status by fluorescence in situ hybridization
in immunohistochemistry-equivocal cases of invasive ductal
carcinoma and aberrant signal patterns: a study at a tertiary
cancer center. Indian J Pathol Microbiol. 54:532–538. 2011.
View Article : Google Scholar
|
|
18.
|
Kowanetz M and Ferrara N: Vascular
endothelial growth factor signaling pathways: therapeutic
perspective. Clin Cancer Res. 12:5018–5022. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
19.
|
Zhao YC, Ni XJ, Wang MH, Zha XM, Zhao Y
and Wang S: Tumor-derived VEGF-C, but not VEGF-D, promotes sentinel
lymph node lymphangiogenesis prior to metastasis in breast cancer
patients. Med Oncol. 29:2594–2600. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20.
|
Linderholm BK, Lindahl T, Holmberg L,
Klaar S, Lennerstrand J, Henriksson R and Bergh J: The expression
of vascular endothelial growth factor correlates with mutant p53
and poor prognosis in human breast cancer. Cancer Res.
61:2256–2260. 2001.PubMed/NCBI
|
|
21.
|
Jobim FC, Schwartsmann G, Xavier NL, et
al: Expression of MMP-9 and VEGF in breast cancer: correlation with
other prognostic indicators. Rev Bras Ginecol Obstet. 30:287–293.
2008.(In Portuguese).
|
|
22.
|
Linderholm BK, Hellborg H, Johansson U, et
al: Significantly higher levels of vascular endothelial growth
factor (VEGF) and shorter survival times for patients with primary
operable triple-negative breast cancer. Ann Oncol. 20:1639–1646.
2009. View Article : Google Scholar
|
|
23.
|
Burness ML, Grushko TA and Olopade Ol:
Epidermal growth factor receptor in triple-negative and basal-like
breast cancer: promising clinical target or only a marker? Cancer
J. 16:23–32. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
24.
|
Kallel I, Khabir A, Boujelbene N, et al:
EGFR overexpression relates to triple negative profile and poor
prognosis in breast cancer patients in Tunisia. J Recept Signal
Transduct Res. 32:142–149. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25.
|
Viale G, Rotmensz N, Maisonneuve P, et al:
Invasive ductal carcinoma of the breast with the ‘triple-negative’
phenotype: prognostic implications of EGFR immunoreactivity. Breast
Cancer Res Treat. 116:317–328. 2009.
|
|
26.
|
Skobe M, Hawighorst T, Jackson DG, et al:
Induction of tumor lymphangiogenesis by VEGF-C promotes breast
cancer metastasis. Nat Med. 7:192–198. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
27.
|
Kazemi M, Salehi Z and Chakosari RJ: TP53
codon 72 polymorphism and breast cancer in northern Iran. Oncol
Res. 18:25–30. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
28.
|
Dookeran KA, Dignam JJ, Ferrer K, et al:
p53 as a marker of prognosis in African-American women with breast
cancer. Ann Surg Oncol. 17:1398–1405. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
29.
|
González-Rodilla I, Verna V, Muñoz AB,
Estévez J, Boix M and Schneider J: Expression of the
apoptosis-related genes Bcl-2 and p53 in clinical samples from
endometrial carcinoma patients. Anticancer Res. 31:4191–4193.
2011.PubMed/NCBI
|
|
30.
|
Mao XY, Fan CF, Zheng HC, Wei J, Yao F and
Jin F: p53 nuclear accumulation and ERalpha expression in ductal
hyperplasia of breast in a cohort of 215 Chinese women. J Exp Clin
Cancer Res. 29:1122010. View Article : Google Scholar : PubMed/NCBI
|
|
31.
|
Tokiniwa H, Horiguchi J, Takata D, et al:
Topoisomerase II alpha expression and the Ki-67 labeling index
correlate with prognostic factors in estrogen receptor-positive and
human epidermal growth factor type-2-negative breast cancer. Breast
Cancer. 19:309–314. 2012. View Article : Google Scholar
|
|
32.
|
Tanner B, Pilch H, Schäffer U, et al:
Expression of c-erbB-2 and topoisomerase II alpha in relation to
chemoresistance in ovarian cancer. Zentralbl Gynakol. 124:176–183.
2002.(In German).
|
|
33.
|
Urruticoechea A, Smith IE and Dowsett M:
Proliferation marker Ki-67 in early breast cancer. J Clin Oncol.
23:7212–7220. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
34.
|
de Azambuja E, Cardoso F, de Castro G Jr,
et al: Ki-67 as prognostic marker in early breast cancer: a
meta-analysis of published studies involving 12,155 patients. Br J
Cancer. 96:1504–1513. 2007.PubMed/NCBI
|
|
35.
|
Dowsett M, Nielsen TO, A’hern R, et al:
Assessment of Ki67 in breast cancer: recommendations from the
International Ki67 in Breast Cancer Working Group. J Natl Cancer
Inst. 103:1656–1664. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
36.
|
Endo Y, Toyama T, Takahashi S, et al: High
estrogen receptor expression and low Ki67 expression are associated
with improved time to progression during first-line endocrine
therapy with aromatase inhibitors in breast cancer. Int J Clin
Oncol. 16:512–518. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
37.
|
Cheang MC, Chia SK, Voduc D, et al: Ki67
index, HER2 status, and prognosis of patients with Luminal B breast
cancer. J Natl Cancer Inst. 101:736–750. 2009. View Article : Google Scholar
|
|
38.
|
Xue C, Wang X, Peng R, et al:
Distribution, clinicopathologic features and survival of breast
cancer subtypes in Southern China. Cancer Sci. 103:1679–1687. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
39.
|
Munjal K, Ambaye A, Evans MF, Mitchell J,
Nandedkar S and Cooper K: Immunohistochemical analysis of ER, PR,
Her2 and CK5/6 in infiltrative breast carcinomas in Indian
patients. Asian Pac J Cancer Prev. 10:773–778. 2009.PubMed/NCBI
|
|
40.
|
Moriya T, Kanomata N, Kozuka Y, et al:
Molecular morphological approach to the pathological study of
development and advancement of human breast cancer. Med Mol
Morphol. 43:67–73. 2010. View Article : Google Scholar : PubMed/NCBI
|
